Parvinder Singh, the promoter of Ranbaxy Laboratories, has sold Rs 15 lakh worth of shares of the company "" equal to three per cent of his stake. Worth a sizeable Rs 65 crore, the shares were placed with Indian investment institutions and banks by JM Financial Consultancy Services. Though the shares sold at a discount of 5.5 per cent on the National Stock Exchange, analysts consider the share price of Rs 650 decent considering the depressed conditions in the market. Singhs stake is expected to decline to 32 per cent; at present, mutual funds hold 14 per cent, the public holds 24 per cent, and banks and institutional investors hold the rest.
The promoter of Ranbaxy is reducing his stake to pay off costly debts incurred since 1993; these include funds borrowed to acquire shares at Rs 400 through warrant rights in a GDR issue. Singh intends to sell a total of about 35 lakh shares in the market. Last year, Ranbaxy had asked Merrill Lynch to sell a seven per cent stake of the promoters to foreign investors. However, the offer fell through due to an unsatisfactory share price.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
